Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

[1]  C. Plass,et al.  The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells , 2009, Leukemia.

[2]  Peter A. Jones,et al.  Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice , 2008, Cancer Prevention Research.

[3]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[4]  Michele D. Sobolewski,et al.  Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines , 2007, Molecular Cancer Therapeutics.

[5]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[6]  S. Sanche,et al.  Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. , 2007, Experimental hematology.

[7]  Steffen Zopf,et al.  Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models , 2007, Scandinavian journal of gastroenterology.

[8]  G. Casey,et al.  Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation , 2007, Molecular Cancer.

[9]  D. Nadal,et al.  Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells , 2007, Molecular Cancer.

[10]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[11]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[12]  Peter A. Jones,et al.  Zebularine: A Unique Molecule for an Epigenetically Based Strategy in Cancer Chemotherapy , 2005, Annals of the New York Academy of Sciences.

[13]  I. Tamm,et al.  Decitabine activates specific caspases downstream of p73 in myeloid leukemia , 2005, Annals of Hematology.

[14]  V. Marquez,et al.  Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. , 2005, Biochemical Pharmacology.

[15]  Dipali Sharma,et al.  Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. , 2005, Molecular endocrinology.

[16]  P. Argani,et al.  Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer* , 2005, Journal of Biological Chemistry.

[17]  Peter A. Jones,et al.  ZEBULARINE: A UNIQUE MOLECULE FOR AN EPIGENETICALLY BASED STRATEGY IN CANCER CHEMOTHERAPY. THE MAGIC OF ITS CHEMISTRY AND BIOLOGY , 2005, Nucleosides, nucleotides & nucleic acids.

[18]  M. Bernstein,et al.  Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia , 2005, Anti-cancer drugs.

[19]  P. Jones,et al.  Zebularine: a new drug for epigenetic therapy. , 2004, Biochemical Society transactions.

[20]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[21]  Peter A. Jones,et al.  Continuous Zebularine Treatment Effectively Sustains Demethylation in Human Bladder Cancer Cells , 2004, Molecular and Cellular Biology.

[22]  Dipali Sharma,et al.  A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine , 2003, Breast Cancer Research and Treatment.

[23]  J. Laliberté,et al.  Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase , 2004, Cancer Chemotherapy and Pharmacology.

[24]  R. Margueron,et al.  Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. , 2003, The Journal of endocrinology.

[25]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[26]  P. Adams,et al.  Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. , 2003, Molecular cell.

[27]  J. Harper,et al.  Coupling of DNA Synthesis and Histone Synthesis in S Phase Independent of Cyclin/cdk2 Activity , 2002, Molecular and Cellular Biology.

[28]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[29]  N. Davidson,et al.  Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Herman,et al.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. , 2000, Cancer research.

[31]  N. C. Price,et al.  Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. , 1999, Journal of molecular biology.

[32]  R. Momparler,et al.  Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells , 1998, Cancer Chemotherapy and Pharmacology.

[33]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[34]  A. Bhagwat,et al.  The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. , 1995, The Biochemical journal.

[35]  Z. Shao,et al.  Expression of estrogen receptors in estrogen receptor–negative human breast carcinoma cells: Modulation of epidermal growth factor‐receptor (EGF‐R) and transforming growth factor α (TGFα) gene expression , 1994, Journal of cellular biochemistry.

[36]  S. Musser,et al.  The decomposition of 1-(.beta.-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) in alkali: mechanism and products , 1992 .

[37]  D. R. Haines,et al.  Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. , 1986, Journal of medicinal chemistry.

[38]  D. Santi,et al.  Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[39]  V. Marquez,et al.  Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase. , 1980, Journal of medicinal chemistry.

[40]  G. Rivard,et al.  Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. , 1979, Cancer research.

[41]  P. Jones,et al.  Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. , 1978, Developmental biology.

[42]  J. Beisler.  Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. , 1978, Journal of medicinal chemistry.

[43]  P. Jones,et al.  Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment , 1977, Nature.